BlinkLab Ltd (ASX:BB1) Shares Rise on Autism Study Results: Here’s Why

Sonal Goyal

11 November 2026 01:16 PM AEDT

BlinkLab Ltd (ASX:BB1) Shares Rise on Autism Study Results: Here’s Why

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

BlinkLab shares traded up 7.02% at $0.610 during the 11 November 2026 trading session.
The exploratory study reported significant differences in smartphone-based tests among individuals with a SHANK2 mutation.
The company said its FDA 510(k) pivotal program for Dx1 is on track and is not changed by the study.

During the Trading session on 11 November 2026, BlinkLab Ltd (ASX:BB1) shares were trading at $0.610 by late morning, up 7.02%. The S&P/ASX 200 (ASX:XJO) was down about 0.06% at 9,123.90 at 12:19 pm over the same period. BlinkLab develops smartphone-based neurometric technology, including its Dx1 platform. On 11 November 2026, the company announced results from a genetic autism study, on the same day as the trading move.

SHANK2 Autism Study Findings

BlinkLab reported that individuals with a SHANK2 mutation, a group of eight participants, showed significant differences in its smartphone tests on sensorimotor gating, startle habituation and spontaneous sensorimotor behaviour. The comparison groups were 99 matched community participants, 10 unaffected siblings, or both.

Biological Validation

The company said SHANK2-related disorder is a genetically defined condition associated with autism. BlinkLab Dx1 measured differences across objective neurophysiological domains, which it said supports the view that its technology captures underlying brain biology rather than behavioural variation alone.

Therapeutic Development

BlinkLab said objective, scalable measures of sensory gating and response dynamics may have future relevance as digital biomarkers and exploratory clinical trial endpoints in genetically defined neurodevelopmental disorders. The company described the result as the first in a series of upcoming readouts from its exploratory research programs.

Regulatory Program

The company said the study used the same core smartphone-based neurometric technology that underpins Dx1, and does not change its FDA 510(k) pivotal program. BlinkLab said it remains on track to announce further study results before the end of the year.

Sector Context

Digital biomarkers and smartphone-based diagnostic tools are an emerging area of neurology and psychiatry research. Companies in this field are typically judged on the strength of their validation data, their regulatory pathways and their ability to attract partners, and small-cap shares can react sharply to study readouts.

Key Risks

The SHANK2 group in this study is small, with eight individuals, and the study is exploratory. Results may not be replicated in larger studies, and the regulatory pathway for Dx1 remains subject to FDA review. BlinkLab will need additional funding to continue its programs, and shares at low prices can be volatile.

What to Watch Ahead

Investors will be looking for further exploratory study readouts before the end of 2026, progress on the FDA 510(k) pivotal program for Dx1 and any partnering or clinical trial endpoint discussions linked to the digital biomarker work.

Final Word

BlinkLab’s trading session on 11 November 2026 came as the company reported exploratory results from a genetic autism study. The company’s upcoming readouts will show how the platform performs across its other research programs.

FAQs

Q: What did BlinkLab report from its SHANK2 study?

A: The company reported significant differences in its smartphone-based tests among eight individuals with a SHANK2 mutation, compared with matched community participants and unaffected siblings.

Q: Does the study change BlinkLab’s regulatory program?

A: The company said the study does not change its FDA 510(k) pivotal program for Dx1.

Q: When will further results be announced?

A: BlinkLab said it remains on track to announce further study results before the end of 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.